caa a22 4500 477057098 CHVBK 20180405111349.0 cr unu---uuuuu 170330e19960501xx s 000 0 eng 10.1007/s002280050088 doi (NATIONALLICENCE)springer-10.1007/s002280050088 Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patientsIV and SC erythropoietin [Elektronische Daten] IV and SC erythropoietin [J. D. Jensen, J. K. Madsen, L. W. Jensen] Objective: The purpose of the study was to investigate the effect of route of administration of erythropoietin (EPO) on the dose requirement in dialysis patients after intravenous (IV) and subcutaneous (SC) therapy. Methods: The study was performed as a single centre, prospective, open, combined parallel and cross-over study of 50 dialysis patients, consecutively randomised to IV or SC treatment with EPO. The initial dose was 40 U⋅kg−1 3-times weekly, adjusted to increase haemoglobin (Hgb) from a median 5.3 mmol⋅l−1 to a target of haemoglobin 6.5-7.5 mmol⋅l−1. After reaching the target level, the haemoglobin was maintained for 4 months (Period 1). Then IV and SC treatment was switched for a further 4 months (Period 2). The study included high risk patients. The adjustment period was completed by 38 patients, Period one by 32 patients (IV/SC = 15/17; male/female = 19/13; age = 54 (24- 71) y), and Period two by 22 patients. Results: No significant difference was found between the two groups in the reticulocyte response, the rate of Hgb increase (IV 0.7 versus SC 0.5, mmol⋅l−1⋅ month−1), time to reach target level (IV 43 versus SC 60 days), or total EPO dose per increase in haemoglobin to target level (IV 663 versus SC 946 (U⋅kg−1) per (mmol Hgb⋅l−1). The overall median maintenance dose during the last month of the two four month periods was 105 (range IV 51-336) U⋅kg−1⋅w−1 and SC 104 (range 21-321) U⋅kg−1⋅w−1. Trough serum EPO levels were significantly higher during SC treatment. The blood pressure did not change significantly from the base level after either route of administration; start 133/80 versus 143/80 mmHg, target 127/78 versus 154/85 mmHg, and maintenance period 140/84 versus 142/85 mmHg. Thus, three-times weekly IV or SC EPO did not differ significantly in efficacy or in the effect on blood pressure in dialysis patients. Springer-Verlag Berlin Heidelberg, 1996 Key words Erythropoietin nationallicence Dialysis nationallicence Renal anaemia nationallicence recombinant human EPO nationallicence intravenous nationallicence subcutaneous nationallicence renin-angiotensin-system nationallicence blood pressure nationallicence Jensen J. D. Department of Nephrology and Medicine C, Skejby Hospital, University Hospital Aarhus, DK-8200 Aarhus N, Denmark, DK aut Madsen J. K. Department of Nephrology and Medicine C, Skejby Hospital, University Hospital Aarhus, DK-8200 Aarhus N, Denmark, DK aut Jensen L. W. Department of Nephrology and Medicine C, Skejby Hospital, University Hospital Aarhus, DK-8200 Aarhus N, Denmark, DK aut https://doi.org/10.1007/s002280050088 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280050088 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Jensen J. D. Department of Nephrology and Medicine C, Skejby Hospital, University Hospital Aarhus, DK-8200 Aarhus N, Denmark, DK aut NATIONALLICENCE 700 1- Madsen J. K. Department of Nephrology and Medicine C, Skejby Hospital, University Hospital Aarhus, DK-8200 Aarhus N, Denmark, DK aut NATIONALLICENCE 700 1- Jensen L. W. Department of Nephrology and Medicine C, Skejby Hospital, University Hospital Aarhus, DK-8200 Aarhus N, Denmark, DK aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer